The Diabetology & Metabolic Care Division is dedicated to providing effective therapeutic solutions for diabetes and metabolic disorders. Our products help patients achieve better glycemic control, improve overall health, and reduce the risk of long-term complications.
Detailed Description
The Diabetology & Metabolic Care Division focuses on the prevention, management, and treatment of diabetes mellitus and related metabolic disorders. Operating through GMP-certified manufacturing facilities and in compliance with DRAP regulations and the Drug Licensing Management (DML) Rules 2019, the division is committed to delivering safe, effective, and high-quality pharmaceutical products.
The division offers innovative therapies that help healthcare professionals manage Type 2 Diabetes Mellitus, insulin resistance, metabolic syndrome, and associated cardiovascular risk factors. Through quality-driven manufacturing, continuous innovation, and patient-centered care, the division aims to support healthier lives and improved treatment outcomes for diabetic patients.
Main Products
Featured Product – Vildagliptin + Metformin
Vildagliptin + Metformin is a combination antidiabetic therapy indicated for the management of Type 2 Diabetes Mellitus. It combines the glucose-lowering effects of a DPP-4 inhibitor and metformin to improve glycemic control, support pancreatic function, and help patients maintain healthy blood sugar levels as part of a comprehensive diabetes management plan.